Eye drop pro­duc­er KC Phar­ma­ceu­ti­cals re­ceives FDA warn­ing let­ter

The FDA sent a warn­ing let­ter to Cal­i­for­nia-based eye drop man­u­fac­tur­er KC Phar­ma­ceu­ti­cals cit­ing sev­er­al is­sues re­lat­ed to the com­pa­ny’s qual­i­ty sys­tem.

In the warn­ing let­ter is­sued at the be­gin­ning of Au­gust, reg­u­la­tors said KC didn’t prop­er­ly per­form smoke stud­ies for its asep­tic pro­cess­ing lines or in­ves­ti­gate and suf­fi­cient­ly ad­dress me­dia fill fail­ures on its fill­ing lines. It al­so not­ed that KC’s “asep­tic pro­cess­ing op­er­a­tion is in­ad­e­quate­ly de­signed to pre­vent con­t­a­m­i­na­tion of your oph­thalmic drug prod­ucts.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER